CN117100729B - Private part antibacterial composition, private part nursing product, and preparation methods and applications thereof - Google Patents
Private part antibacterial composition, private part nursing product, and preparation methods and applications thereof Download PDFInfo
- Publication number
- CN117100729B CN117100729B CN202311350774.2A CN202311350774A CN117100729B CN 117100729 B CN117100729 B CN 117100729B CN 202311350774 A CN202311350774 A CN 202311350774A CN 117100729 B CN117100729 B CN 117100729B
- Authority
- CN
- China
- Prior art keywords
- aspartic acid
- rape
- bacteriostatic
- composition
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 238000002360 preparation method Methods 0.000 title claims abstract description 40
- 230000000844 anti-bacterial effect Effects 0.000 title abstract description 38
- 230000000474 nursing effect Effects 0.000 title abstract description 9
- 238000004519 manufacturing process Methods 0.000 title description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract description 49
- 235000003704 aspartic acid Nutrition 0.000 claims abstract description 49
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims abstract description 49
- ZUHZZVMEUAUWHY-UHFFFAOYSA-N n,n-dimethylpropan-1-amine Chemical compound CCCN(C)C ZUHZZVMEUAUWHY-UHFFFAOYSA-N 0.000 claims abstract description 41
- 230000003385 bacteriostatic effect Effects 0.000 claims abstract description 39
- 235000020767 valerian extract Nutrition 0.000 claims abstract description 38
- FATBGEAMYMYZAF-KTKRTIGZSA-N oleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(N)=O FATBGEAMYMYZAF-KTKRTIGZSA-N 0.000 claims abstract description 35
- FATBGEAMYMYZAF-UHFFFAOYSA-N oleicacidamide-heptaglycolether Natural products CCCCCCCCC=CCCCCCCCC(N)=O FATBGEAMYMYZAF-UHFFFAOYSA-N 0.000 claims abstract description 35
- 241000207201 Gardnerella vaginalis Species 0.000 claims abstract description 16
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 13
- 241000222122 Candida albicans Species 0.000 claims abstract description 12
- 229940095731 candida albicans Drugs 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 150000001408 amides Chemical class 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 5
- 229920002148 Gellan gum Polymers 0.000 claims description 5
- 239000004373 Pullulan Substances 0.000 claims description 5
- 229920001218 Pullulan Polymers 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 229920001577 copolymer Polymers 0.000 claims description 5
- -1 di-decyl tetradecyl Chemical group 0.000 claims description 5
- 239000000216 gellan gum Substances 0.000 claims description 5
- 235000010492 gellan gum Nutrition 0.000 claims description 5
- 235000011187 glycerol Nutrition 0.000 claims description 5
- 235000019423 pullulan Nutrition 0.000 claims description 5
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N 1-Tetradecanol Natural products CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 claims description 4
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000010499 rapseed oil Substances 0.000 claims description 2
- 239000000828 canola oil Substances 0.000 claims 1
- 235000019519 canola oil Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 208000015181 infectious disease Diseases 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000004926 Bacterial Vaginosis Diseases 0.000 abstract description 4
- 208000037009 Vaginitis bacterial Diseases 0.000 abstract description 4
- 231100000344 non-irritating Toxicity 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 230000007794 irritation Effects 0.000 description 10
- 238000004659 sterilization and disinfection Methods 0.000 description 9
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 230000001954 sterilising effect Effects 0.000 description 8
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 8
- 210000004877 mucosa Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 5
- 239000003093 cationic surfactant Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000001384 succinic acid Substances 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 208000031888 Mycoses Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 208000006374 Uterine Cervicitis Diseases 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 206010008323 cervicitis Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 231100000017 mucous membrane irritation Toxicity 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241001522296 Erithacus rubecula Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000207202 Gardnerella Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 1
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 1
- 229920002413 Polyhexanide Polymers 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000007313 Reproductive Tract Infections Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229930014456 matrine Natural products 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/84—Valerianaceae (Valerian family), e.g. valerian
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Urology & Nephrology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Medicines Containing Plant Substances (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
The invention discloses a private part antibacterial composition, a private part nursing product, and a preparation method and application thereof. The invention provides a bacteriostatic composition containing rape oleamide propyl dimethylamine, aspartic acid and valerian extracts, which is mild and non-irritating, can effectively inhibit staphylococcus aureus, candida albicans and gardnerella vaginalis, has a bacteriostatic rate higher than 99%, can be used for private care, and is used for preventing and treating diseases caused by staphylococcus aureus, candida albicans or gardnerella vaginalis infection. In addition, on the basis of the antibacterial composition, related antibacterial products can be developed, and the antibacterial composition can be used for effectively preventing and treating bacterial vaginosis caused by gardnerella vaginalis infection and the like.
Description
Technical Field
The invention belongs to the technical field of antibacterial products. More particularly, relates to a private part antibacterial composition, a private part nursing product, a preparation method and application thereof.
Background
The inflammation of private parts caused by bacterial and fungal infection not only affects the health of females, but also brings inconvenience to the lives of females. Such as candida albicans, gardnerella vaginalis, etc., are common pathogenic bacteria for female genital tract infection, and can cause bacterial vaginosis, cervicitis, etc.
The traditional antibacterial agent for female private parts mostly adopts substances with strong bactericidal capacity such as chlorhexidine gluconate, benzalkonium chloride, matrine and the like and large irritation, and can cause the disorder of flora of the private parts, aggravate the problems of itching, dryness and the like after long-term use. Therefore, a private antibacterial agent with good antibacterial effect and mild antibacterial effect needs to be provided.
The cationic surfactant is a kind of cationic surfactant capable of generating hydrophobicity in water, has good emulsifying, wetting, washing, sterilizing, softening, antistatic and corrosion-resistant performances, and is widely applied to the technical fields of daily chemical industry, food, agriculture, medicine and the like. At present, although a private antibacterial lotion using a cationic surfactant (such as polyhexamethylene biguanide hydrochloride) as a main antibacterial agent exists, the cationic surfactant has a safety risk, is not specific to gardnerella vaginalis, and cannot meet the requirements for preventing or treating bacterial vaginosis, cervicitis and the like.
Disclosure of Invention
Aiming at the technical problems, the invention provides a bacteriostatic composition capable of inhibiting staphylococcus aureus, candida albicans and gardnerella vaginalis. Meanwhile, the antibacterial nursing product which is mild, has no stimulation and has a relieving effect, and the preparation method and the application thereof are provided.
It is a first object of the present invention to provide a bacteriostatic composition.
A second object of the present invention is to provide the use of said composition for the preparation of a product for inhibiting bacteria, in particular staphylococcus aureus, candida albicans and/or gardnerella vaginalis.
A third object of the present invention is to provide a bacteriostatic care product.
A fourth object of the present invention is to provide a method for preparing the bacteriostatic care product.
The above object of the present invention is achieved by the following technical scheme:
according to the invention, a great deal of researches show that the water solution of rape oleamide propyl dimethylamine has no antibacterial effect, but shows cationic antibacterial effect in a weak acid system formed by aspartic acid water solution. Further experiments show that the rape oleamide propyl dimethylamine only shows obvious antibacterial effect in a weak acid system formed by aspartic acid aqueous solution, but has no obvious antibacterial effect in a weak acid system formed by organic acids such as citric acid, lactic acid, succinic acid and the like.
On the basis, the invention further improves the antibacterial effect of the rape oleamide propyl dimethylamine and the aspartic acid by compounding the valerian extract, reduces the irritation of the rape oleamide propyl dimethylamine and the aspartic acid, reduces the irritation from extremely light irritation to no irritation, is suitable for nursing and using in female private parts, and can be used for preventing and treating diseases caused by infection of staphylococcus aureus, candida albicans or gardnerella vaginalis and the like.
Accordingly, the present invention claims a bacteriostatic composition comprising rape oleamide propyldimethylamine and aspartic acid.
Preferably, the mass ratio of the rape oleamide propyl dimethylamine to the aspartic acid is 0.1-10: 0.1 to 10.
More preferably, valerian extracts are also included in the bacteriostatic composition.
The rape oleamide propyl dimethylamine, the aspartic acid and the valerian extracts are compounded according to a certain proportion, so that not only can staphylococcus aureus, candida albicans and gardnerella vaginalis be effectively inhibited, but also the rape oleamide propyl dimethylamine, the aspartic acid and the valerian extracts have the advantages of mildness and no stimulation.
Specifically, the mass ratio of the rape oleamide propyl dimethylamine, the aspartic acid to the valerian extract is 0.1-10: 0.1 to 10:0.1 to 10.
Preferably, the mass ratio of the rape oleamide propyl dimethylamine, the aspartic acid to the valerian extract is 1-10: 1 to 10:1 to 10.
Further preferably, the mass ratio of the rape oleamide propyl dimethylamine, the aspartic acid and the valerian extract is 3-10: 3-10: 3 to 10.
Specifically, the antibacterial composition also comprises a solvent; wherein, the total mass ratio of the rape oleamide propyl dimethylamine, the aspartic acid and the valerian extract is 0.3-30 percent.
Optionally, the solvent is water.
The invention also claims the application of the composition in preparing antibacterial products.
In particular, the bacteriostatic product refers to a product that inhibits staphylococcus aureus, candida albicans and/or gardnerella vaginalis.
The invention also claims the use of said composition for the preparation of a medicament for the prevention and/or treatment of bacterial diseases.
In particular, the bacterial disease is a disease caused by staphylococcus aureus and/or gardnerella vaginalis infection.
The invention also claims the use of said composition for the preparation of a medicament for the prevention and/or treatment of fungal diseases.
In particular, the fungal disease is a disease caused by candida albicans infection.
The invention also provides a bacteriostatic care product which is prepared from the composition and other acceptable auxiliary materials.
Specifically, the antibacterial care product provided by the invention is antibacterial care gel, and can be used as a private care product. Specifically, the antibacterial nursing gel comprises the following components in percentage by mass: PEG-240/HDI copolymer di-decyl tetradecyl alcohol polyether-20-10%, gellan gum water solution 0.5-5%, pullulan water solution 6-10%, butanediol 4.5-10%, glycerin 7.5-15%, valerian extract 3-10%, rape flower amide propyl dimethylamine 3-10%, aspartic acid 3-10%, and the rest is solvent.
More specifically, the composition comprises the following components in percentage by mass: PEG-240/HDI copolymer di-decyl tetradecanoyl polyether-20%, gellan gum 0.5%, pullulan 3%, butylene glycol 4.5%, glycerin 7.5%, valerian extract 3%, rape flower amide propyl dimethylamine 3%, aspartic acid 3%, and water in balance.
The invention also provides a preparation method of the nursing gel, which comprises the following steps:
s1, sequentially adding PEG-240/HDI copolymer di-decyl tetradecyl alcohol polyether-20, 0.5% gellan gum aqueous solution, 3% pullulan aqueous solution, butanediol, glycerol, rape flower amide propyl dimethylamine and aspartic acid into water at the temperature of 79-82 ℃ and uniformly mixing;
s2, reducing the temperature of the mixture obtained in the step S2 to below 40 ℃, and adding valerian extract for uniform mixing.
The invention has the following beneficial effects:
the invention provides a bacteriostatic composition containing rape oleamide propyl dimethylamine, aspartic acid and valerian extracts, which is mild and non-irritating, can effectively inhibit staphylococcus aureus, candida albicans and gardnerella vaginalis, has a bacteriostatic rate higher than 99%, can be used for private care, and is used for preventing and treating diseases caused by staphylococcus aureus, candida albicans or gardnerella vaginalis infection. On the basis of the antibacterial composition, the invention also provides a specific mild and comfortable antibacterial nursing gel which can be used as a private care product to effectively prevent and treat bacterial vaginosis caused by gardnerella vaginalis infection and the like.
Detailed Description
The present invention is further illustrated below with reference to specific examples, which are not intended to limit the invention in any way. Unless specifically stated otherwise, the reagents, methods and apparatus employed in the present invention are those conventional in the art.
Reagents and materials used in the following examples are commercially available unless otherwise specified.
The rape oleamide propyl dimethylamine used in the embodiment of the invention is a product of Inolex corporation in America; the aspartic acid is an Anhui Hua Heng biological company product; the valerian extract is a Guangzhou cosmetic company product.
The strain used for testing the sterilization rate comprises the following steps: staphylococcus aureus [ (S.aureus ]Staphylococcus aureusATCC 6538) and Candida albicansCandida albicans（Robin）BerkhoutATCC 10231) and gardnerella vaginalisGardnerellaVaginalisATCC 14018), the above strains were purchased from the Shanghai collection biotechnology center.
Example 1 preparation of bacteriostatic composition 1
The embodiment provides a bacteriostatic composition which comprises 0.1% of rape oleamide propyl dimethylamine, 0.1% of aspartic acid and 0.1% of valerian extract by mass ratio.
The preparation method comprises the following steps: the rape oleamide propyl dimethylamine, the aspartic acid and the valerian extract are respectively taken and dissolved in water, and the water is used for supplementing 100 percent.
Example 2 preparation of bacteriostatic composition 2
The embodiment provides a bacteriostatic composition which comprises 0.5% of rape oleamide propyl dimethylamine, 0.5% of aspartic acid and 0.5% of valerian extract by mass ratio.
The preparation method is the same as in example 1.
Example 3 preparation of bacteriostatic composition 3
The embodiment provides a bacteriostatic composition which comprises 1% of rape oleamide propyl dimethylamine, 1% of aspartic acid and 1% of valerian extract by mass ratio.
The preparation method is the same as in example 1.
Example 4 preparation of bacteriostatic composition 4
The embodiment provides a bacteriostatic composition which comprises 2% of rape oleamide propyl dimethylamine, 2% of aspartic acid and 2% of valerian extract by mass ratio.
The preparation method is the same as in example 1.
Example 5 preparation of bacteriostatic composition 5
The embodiment provides a bacteriostatic composition which comprises 3% of rape oleamide propyl dimethylamine, 3% of aspartic acid and 3% of valerian extract by mass ratio.
The preparation method is the same as in example 1.
Example 6 preparation of bacteriostatic composition 6
The embodiment provides a bacteriostatic composition which comprises 5% of rape oleamide propyl dimethylamine, 5% of aspartic acid and 5% of valerian extract by mass ratio.
The preparation method is the same as in example 1.
Example 7 preparation of bacteriostatic composition 7
The embodiment provides a bacteriostatic composition which comprises 6% of rape oleamide propyl dimethylamine, 6% of aspartic acid and 6% of valerian extract by mass ratio.
The preparation method is the same as in example 1.
Example 8 preparation of bacteriostatic composition 8
The embodiment provides a bacteriostatic composition which comprises 10% of rape oleamide propyl dimethylamine, 10% of aspartic acid and 10% of valerian extract by mass ratio.
The preparation method is the same as in example 1.
Example 9 preparation of bacteriostatic composition 9
The embodiment provides a bacteriostatic composition which comprises 1% of rape oleamide propyl dimethylamine, 5% of aspartic acid and 10% of valerian extract by mass ratio.
The preparation method is the same as in example 1.
Example 10 preparation of bacteriostatic composition 10
The embodiment provides a bacteriostatic composition which comprises 10% of rape oleamide propyl dimethylamine, 5% of aspartic acid and 1% of valerian extract by mass ratio.
The preparation method is the same as in example 1.
EXAMPLE 11 preparation of bacteriostatic composition 11
The embodiment provides a bacteriostatic composition which comprises 5% of rape oleamide propyl dimethylamine, 10% of aspartic acid and 1% of valerian extract by mass ratio.
The preparation method is the same as in example 1.
Comparative example 1
An antibacterial composition comprises 0.1% of rape oleamide propyl dimethylamine by mass ratio.
The preparation method is the same as in example 1.
Comparative example 2
An antibacterial composition comprises 0.1% aspartic acid by mass ratio.
The preparation method is the same as in example 1.
Comparative example 3
A bacteriostatic composition comprises 0.1% of valerian extract by mass.
The preparation method is the same as in example 1.
Comparative example 4
An antibacterial composition comprises 0.1% rape oleamide propyl dimethylamine and 0.1% aspartic acid according to mass ratio.
The preparation method is the same as in example 1.
Comparative example 5
An antibacterial composition comprises, by mass, 0.1% rape oleoamidopropyl dimethylamine and 0.1% valerian extract.
The preparation method is the same as in example 1.
Comparative example 6
An antibacterial composition comprises, by mass, 0.1% aspartic acid and 0.1% valerian extract.
The preparation method is the same as in example 1.
Comparative example 7
The same as in example 1, except that the aspartic acid was replaced with an equal amount of citric acid.
Comparative example 8
The same as in example 1, except that the same amount of lactic acid was used instead of aspartic acid.
Comparative example 9
The same as in example 1, except that aspartic acid was replaced with an equal amount of succinic acid.
Comparative example 10
The same as in comparative example 4, except that the aspartic acid was replaced with an equal amount of citric acid.
Comparative example 11
The difference is that the aspartic acid is replaced with an equal amount of lactic acid as in comparative example 4.
Comparative example 12
The difference is that the aspartic acid is replaced with an equal amount of succinic acid as in comparative example 4.
Comparative example 13
The same as in example 1 was followed except that rape oil amidopropyl dimethylamine was replaced with an equal amount of cocamidopropyldimethylamine.
The compositions of examples 1 to 11 and comparative examples 1 to 13 above are summarized in Table 1:
TABLE 1
Example 12 antibacterial Effect test
The invention refers to a microbial killing experimental method of disinfection technical Specification (2002 edition), and the antibacterial compositions of examples 1 to 11 and the antibacterial compositions of comparative examples 1 to 13 are respectively tested for killing rates of staphylococcus aureus, candida albicans and gardnerella vaginalis, and the results are shown in the following table 2:
TABLE 2 results of the sterilization rate test
As is clear from the results of comparative examples 4 and comparative examples 10 to 12, it is apparent from Table 2 that rape oleamide propyldimethylamine has a remarkable bactericidal effect under the weakly acidic condition of aspartic acid formation, but does not have such a phenomenon in the presence of other organic acids such as citric acid, lactic acid, succinic acid and the like. Meanwhile, as shown in comparative examples 1 and 4, the sterilization rate of the antibacterial composition can be obviously improved by adding valerian extract based on rape oleamide propyl dimethylamine and aspartic acid, and the sterilization rate is also improved along with the increase of the contents of rape oleamide propyl dimethylamine, aspartic acid and valerian extract (examples 1-8), so that the antibacterial composition has ideal antibacterial effect when compounded within a certain concentration range.
EXAMPLE 13 vaginal mucosa irritation test
Based on rape oleamide propyl dimethylamine and aspartic acid, the invention not only compounds valerian extract, but also compounds other components in the vaginal antibacterial product, and different compositions shown in table 3 are obtained. The irritation of the different compositions shown in table 3 to the vaginal mucosa was tested by referring to the vaginal mucosa irritation test method in the disinfection technical Specification (2002 edition).
TABLE 3 Table 3
The results of the vaginal mucosa stimulation experiments for the different compositions shown in table 3 are shown in table 4 below:
TABLE 4 results of vaginal mucosal irritation experiments with different compositions
Example 14 preparation of a privates care gel and Sterilization and vaginal mucosal irritation test thereof
The invention also provides a private care gel based on rape oleamide propyl dimethylamine, aspartic acid and valerian extracts, and the formula of the private care gel is shown in table 5:
TABLE 5
The preparation method of the private care gel comprises the following steps:
(1) adding the component 9 into a beaker, heating to 79-82 ℃, sequentially adding the component 1, the component 2, the components 3, 4 and 5, and uniformly stirring;
(2) and sequentially adding the components 7 and 8, uniformly stirring, and adding the component 6 when the temperature is reduced to below 40 ℃.
The sterilization rate and the irritation to the vaginal mucosa of the private care gel are tested by referring to a microbial killing test method and a vaginal mucosa irritation test method in the technical Specification for sterilization (2002 edition), and the results are shown in the following table 6:
TABLE 6
The above examples are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above examples, and any other changes, modifications, substitutions, combinations, and simplifications that do not depart from the spirit and principle of the present invention should be made in the equivalent manner, and the embodiments are included in the protection scope of the present invention.
Claims (7)
1. A bacteriostatic composition comprising canola oil amidopropyl dimethylamine, aspartic acid and valerian extract; the mass ratio of the rape oleamide propyl dimethylamine, the aspartic acid to the valerian extract is 1-10: 1 to 10:1 to 10.
2. The composition of claim 1, further comprising a solvent; the total mass ratio of the rape oil amide propyl dimethylamine, the aspartic acid and the valerian extract is 0.3-30%.
3. Use of a composition according to claim 1 or 2 for the preparation of a bacteriostatic product.
4. Use according to claim 3, wherein the bacteriostatic product is a product inhibiting staphylococcus aureus, candida albicans and/or gardnerella vaginalis.
5. A bacteriostatic care product, characterized in that it is prepared from the composition according to claim 1 or 2 and other acceptable excipients.
6. The product according to claim 5, comprising the following components in percentage by mass: PEG-240/HDI copolymer di-decyl tetradecyl alcohol polyether-20-10%, gellan gum water solution 0.5-5%, pullulan water solution 6-10%, butanediol 4.5-10%, glycerin 7.5-15%, valerian extract 3-10%, rape flower amide propyl dimethylamine 3-10%, aspartic acid 3-10%, and water in balance.
7. The product of claim 6, prepared by a process comprising the steps of:
s1, sequentially adding PEG-240/HDI copolymer di-decyl tetradecyl alcohol polyether-20, 0.5% gellan gum aqueous solution, 3% pullulan aqueous solution, butanediol, glycerol, rape flower amide propyl dimethylamine and aspartic acid into water at the temperature of 79-82 ℃ and uniformly mixing;
s2, reducing the temperature of the mixture obtained in the step S2 to below 40 ℃, and adding valerian extract for uniform mixing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311350774.2A CN117100729B (en) | 2023-10-18 | 2023-10-18 | Private part antibacterial composition, private part nursing product, and preparation methods and applications thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311350774.2A CN117100729B (en) | 2023-10-18 | 2023-10-18 | Private part antibacterial composition, private part nursing product, and preparation methods and applications thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117100729A CN117100729A (en) | 2023-11-24 |
| CN117100729B true CN117100729B (en) | 2024-01-26 |
Family
ID=88796806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311350774.2A Active CN117100729B (en) | 2023-10-18 | 2023-10-18 | Private part antibacterial composition, private part nursing product, and preparation methods and applications thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117100729B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105380831A (en) * | 2015-12-15 | 2016-03-09 | 广州温雅日用化妆品有限公司 | Mild nursing hair oil treatment and care composition containing no silicone oil and preparation method of mild nursing hair oil treatment and care composition |
| CN111616978A (en) * | 2020-07-16 | 2020-09-04 | 马祥全 | Application of brassinosteroids as emulsifier in cosmetics |
| CN112353877A (en) * | 2020-12-14 | 2021-02-12 | 武汉惠尔生物科技有限公司 | Application of valerian total alkaloid extract in preparation of malassezia inhibitor |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11458084B2 (en) * | 2020-02-28 | 2022-10-04 | L'oreal | Hair cleansing composition |
| US20220202674A1 (en) * | 2020-12-29 | 2022-06-30 | L'oreal | Cosmetic and personal care compositions containing cationic surfactants and anionic compounds |
-
2023
- 2023-10-18 CN CN202311350774.2A patent/CN117100729B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105380831A (en) * | 2015-12-15 | 2016-03-09 | 广州温雅日用化妆品有限公司 | Mild nursing hair oil treatment and care composition containing no silicone oil and preparation method of mild nursing hair oil treatment and care composition |
| CN111616978A (en) * | 2020-07-16 | 2020-09-04 | 马祥全 | Application of brassinosteroids as emulsifier in cosmetics |
| CN112353877A (en) * | 2020-12-14 | 2021-02-12 | 武汉惠尔生物科技有限公司 | Application of valerian total alkaloid extract in preparation of malassezia inhibitor |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117100729A (en) | 2023-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3777499B2 (en) | Antifungal composition | |
| EP2775838B1 (en) | Aqueous antimicrobial composition containing coniferous resin acids | |
| US8765819B2 (en) | Composition comprising benzoic acid in combination with organic acid preservatives as active ingredients and the use thereof | |
| JP2001505546A (en) | Antibacterial treatment for herpes simplex virus and other infectious diseases | |
| CN112263499B (en) | Animal flavor wave with antibacterial function and preparation method thereof | |
| KR20070092095A (en) | Disinfection compositions and methods for their preparation and use | |
| AU2019355862A1 (en) | Therapeutic compositions | |
| CN102113981B (en) | A kind of non-rinsing pregnant woman's perineal medical care gel and preparation method thereof | |
| JP6941329B1 (en) | Marbofloxacin spray and manufacturing method | |
| MXPA06001411A (en) | Topical veterinary compositions and methods for the treatment and prevention of infection. | |
| WO2008104076A1 (en) | Electrocolloidal silver and echinacea root antimicrobial formulation | |
| WO2006001766A1 (en) | Composition comprising lactic acid and lactoferrin | |
| CN112999331A (en) | Preparation method and application of biological sterilization preparation | |
| CN117100729B (en) | Private part antibacterial composition, private part nursing product, and preparation methods and applications thereof | |
| CN106176603A (en) | A kind of plants essential oil micro emulsion gel and its preparation method and application | |
| RU2423989C2 (en) | Agent for treating dugs | |
| CN106267329A (en) | A kind of plants essential oil gel dressing and its preparation method and application | |
| CN105582529B (en) | Pharmaceutical composition for treating beriberi | |
| CN109985063B (en) | Efficient antibacterial pharmaceutical composition and preparation method and application thereof | |
| CN106266037B (en) | Liquid gel and preparation method thereof | |
| CN105560374A (en) | Compound preparation for treating dairy cow mammitis and preparation method thereof | |
| RU2367425C1 (en) | Cream for milking ''dennica'' | |
| CN113230205B (en) | Gynecological gel preparation and preparation method and application thereof | |
| CN108186705A (en) | A kind of anti-inflammatory gelling agent and preparation method thereof | |
| CN113413331B (en) | Anti-acne composition and its preparation and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |